2026-06-14T06:44:00Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/202512024-11-28T17:58:31Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16961col_20.500.12105_16967
Repisalud author Lainez, Nuria author Garcia-Donas, Jesus author Esteban, Emilio author Puente, Javier author Isabel Saez, M author Gallardo, Enrique author Pinto-Marin, Alvaro author Vazquez-Estevez, Sergio author Leon, Luis author Garcia-Carbonero, Icar author Suarez-Rodriguez, Cristina author Molins, Carmen author Climent-Duran, Miguel A author Lazaro-Quintela, Martin author Gonzalez del Alba, Aranzazu author Jose Mendez-Vidal, Maria author Chirivella, Isabel author Afonso, Francisco J author Lopez-Brea, Marta author Sala-Gonzalez, Nuria author Domenech, Montserrat author Basterretxea, Laura author Santander-Lobera, Carmen author Gil-Arnaiz, Irene author Fernandez, Ovidio author Caballero-Diaz, Cristina author Mellado, Begona author Marrupe, David author Garcia-Sanchez, Jose author Sanchez-Escribano, Ricardo author Fernandez Parra, Eva author Villa Guzman, Jose C author Martinez-Ortega, Esther author Belen Gonzalez, Maria author Moran, Marina author Suarez-Paniagua, Beatriz author Lecumberri, Maria J author Castellano, Daniel 2024-07-09T09:13:09Z 2024-07-09T09:13:09Z 2016-02-22 Lainez N, Garcia-Donas J, Esteban E, Puente J, Isabel Saez M, Gallardo E, et al. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study. BMC Cancer. 2016 Feb 22;16:135. 10.1186/s12885-016-2084-9 1471-2407 BMC Cancer http://hdl.handle.net/20.500.13003/10464 26906039 L608822416 2-s2.0-84959460559 http://hdl.handle.net/20.500.12105/20251 370471600003 Background: The impact of such recommendations after their implementation of guidelines has not usually been evaluated. Herein, we assessed the impact and compliance with the Spanish Oncology Genitourinary Group (SOGUG) Guidelines for toxicity management of targeted therapies in metastatic renal cell carcinoma (mRCC) in daily clinical practice. Methods: Data on 407 mRCC patients who initiated first-line targeted therapy during the year before and the year after publication and implementation of the SOGUG guideline program were available from 34 Spanish Hospitals. Adherence to SOGUG Guidelines was assessed in every cycle. Results: Adverse event (AE) management was consistent with the Guidelines as a whole for 28.7 % out of 966 post-implementation cycles compared with 23.1 % out of 892 pre-implementation cycles (p = 0.006). Analysis of adherence by AE in non-compliant cycles showed significant changes in appropriate management of hypertension (33 % pre-implementation vs. 44.5 % post-implementation cycles; p < 0.0001), diarrhea (74.0 % vs. 80.5 %; p = 0.011) and dyslipemia (25.0 % vs. 44.6 %; p < 0.001). Conclusions: Slight but significant improvements in AE management were detected following the implementation of SOGUG recommendations. However, room for improvement in the management of AEs due to targeted agents still remains and could be the focus for further programs in this direction. eng Adverse events Guidelines Renal cell carcinoma Targeted therapy Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study research article